Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma Clinical Trial

Official title:

Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05078775
• Other study ID #: NEAAR-001
• Status: Recruiting
• Phase: N/A
• Start date: December 21, 2021
• Est. completion date: December 2024

Study information

• Verified date: February 2024
• Source: Faeth Therapeutics
• Contact: Faeth Therapeutics
• Phone: (708) 406-9282
• Email: info[@]faeththerapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Signed informed consent form (ICF) by subject.

2. Histologically or cytologically confirmed pancreatic adenocarcinoma.

3. Locally advanced and unresectable or metastatic pancreatic adenocarcinoma.

4. Eligible for standard of care treatment with the gem+nabP regimen.

5. 18 years of age or older.

6. Measurable disease as determined by RECIST 1.1 (at least one measurable lesion must not have been irradiated in the past).

7. ECOG Performance Status of = 1.

8. Adequate organ function during screening evaluation

9. Available pancreatic adenocarcinoma tissue samples from a primary or metastatic site that has been biopsied within the last 12 months and provide consent for them to be obtained and analyzed by the study sponsor to assist in determining final eligibility. A minimum of five (ten preferred) formalin fixed paraffin embedded (FFPE) archival or fresh tumor tissue slides are required.

Key Exclusion Criteria:

1. Any prior neoadjuvant or adjuvant therapy for pancreatic cancer within 6 months of screening.

2. Any prior therapy for metastatic pancreatic cancer or locally advanced and unresectable pancreatic cancer (except for neoadjuvant or adjuvant therapy as noted above in exclusion criteria 1)

3. Known cerebral metastasis.

4. Diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to beginning the NEAAR medical food).

5. Body mass index (BMI) <18.5 kg/m2 or >40 kg/m2 or serious or refractive cachexia or anorexia that, in the investigator's judgment, prohibits subjects from having energy or appetite sufficient to reliably engage in a strict medical food regimen for an extended time.

6. Presence of any significant comorbidity including clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication), myocardial infarction or unstable angina within the 12 months prior to screening, or any major organ failure.

7. Known hypersensitivity, allergy, or religious restrictions regarding pork or pork-derived products; or known allergy to any of the major food allergens as defined by U.S. law (milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame); or known allergy or hypersensitivity to , gemcitabine or nab-paclitaxel, PERT products (e.g., Pancreaze), or formulary excipients in these products (refer to the FDA-approved package insert).

8. Major surgery or significant traumatic injury within 14 days of planned start of NEAAR medical food or the anticipation of the need for a major surgical procedure during the study.

9. Unwillingness to consume small quantities of meat products and byproducts (e.g., fish sauce, bone marrow, chicken broth).

10. Diagnosed with an eating disorder, irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis, or gluten-sensitive enteropathy.

Related Conditions & MeSH terms

• Adenocarcinoma
• Locally Advanced Unresectable Pancreatic Adenocarcinoma
• Metastatic Pancreatic Adenocarcinoma

Intervention

Other:
• NEAAR Medical Food
Standardized non-essential amino acid restricted medical food.

Locations

Country	Name	City	State
United States	Baptist Hospitals of Southeast Texas	Beaumont	Texas
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Oncology Physicians Network	Glendale	California
United States	Cedars-Sinai	Los Angeles	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Atlantic Health	Morristown	New Jersey
United States	Sarah Cannon	Nashville	Tennessee
United States	Hoag Memorial Hospital Presbyterian	Newport Beach	California
United States	xCures - Virtual Site	Raleigh	North Carolina
United States	Louisiana State University Health Sciences Center	Shreveport	Louisiana
United States	Baylor Scott & White Health	Temple	Texas
United States	University of Arizona Cancer Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Faeth Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstrate tolerability of the NEAAR medical food.	The primary endpoint is the rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food.	Through study completion (average of 6 months)
Secondary	Overall response rates	Complete response and partial response using RECIST 1.1	Through study completion (average of 6 months)
Secondary	Duration of best response		Through study completion (average of 6 months)
Secondary	Changes in biomarkers	Absolute and relative change from baseline of disease biomarkers	Through study completion (average of 6 months)
Secondary	Progression-free survival	Duration from radiographic documentation of disease to radiographic documentation of progression or death from any cause	Through study completion (average of 6 months)